Compare Ascendis Pharma A/S (ASND) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Royal Bank of Canada — how do they compare? Ascendis Pharma A/S trades at $255.19 (market cap $16.67B), while Royal Bank of Canada trades at $212.65 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 17.5× Ascendis Pharma A/S's market cap, and Royal Bank of Canada pays a 2.37% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RY | |
|---|---|---|
Market Cap | $16.67B | $292.32B |
Sector | Health | Financials |
52-Week High | $277.18 | $217.87 |
52-Week Low | $189.74 | $134.80 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Royal Bank of Canada (RY) trades at $212.67, up 0.89% today, with a bullish technical signal and recent quarterly earnings beats. The stock shows strong fundamentals with 2025 revenue of $66.53B and net income of $20.36B, yielding a 31.85% net margin. Analyst consensus is mixed with 43% buy ratings, while recent news highlights insider selling and dividend declarations.
RY presents a solid investment case with robust profitability and dividend appeal, but risks include high valuation multiples and mixed institutional sentiment. Upside is supported by earnings momentum, though macroeconomic and competitive pressures warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
